Results of African malaria vaccine trial expected later this year

NewsGuard 100/100 Score

The final phase of testing for GlaxoSmithKline Biologicals' malaria vaccine, RTS,S, is underway in seven sub-Saharan African countries, and "[i]f the results, due to be released later this, year confirm the vaccine's efficacy in preventing malaria, it could be made available as early as 2015," IRIN reports.

"A malaria vaccine would not only save lives, it would also alleviate the great burden of the disease on health systems in economically stretched developing countries," IRIN writes (6/20). Christian Loucq, director of the PATH Malaria Vaccine Initiative, which is helping to fund the trials, "says the new vaccine … will be a major step toward getting rid of malaria. But for that to happen, he says, greater investment in research will be essential," VOA News notes (Sinha, 6/20).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Oxford University and Brazil partner to advance malaria vaccine development